Atomo Diagnostics Beheer

Beheer criteriumcontroles 4/4

De CEO Atomo Diagnostics is John Kelly, benoemd in Jan2010, heeft een ambtstermijn van 14.83 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 476.48K, bestaande uit 85.2% salaris en 14.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.15% van de aandelen van het bedrijf, ter waarde A$ 147.41K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 4.8 jaar.

Belangrijke informatie

John Kelly

Algemeen directeur

AU$476.5k

Totale compensatie

Percentage CEO-salaris	85.2%
Dienstverband CEO	14.8yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 01

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Feb 26

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

Dec 18

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Jul 16

Analyse CEO-vergoeding

Hoe is John Kelly's beloning veranderd ten opzichte van Atomo Diagnostics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$476k	AU$406k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$542k	AU$417k	-AU$10m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$533k	AU$368k	-AU$6m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$6m
Jun 30 2021	AU$467k	AU$372k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$10m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$611k	AU$298k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$7m
Dec 31 2019	n/a	n/a	-AU$5m
Sep 30 2019	n/a	n/a	-AU$5m
Jun 30 2019	AU$319k	AU$248k	-AU$5m

Compensatie versus markt: De totale vergoeding ($USD 309.36K ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 298.27K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Kelly

14.8yrs

Tenure

AU$476,477

Compensatie

Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Kelly	Founder	14.8yrs	AU$476.48k	1.15% A$ 147.4k
Chandra Sukumar	Chief Operating Officer	2.6yrs	AU$303.92k	0.027% A$ 3.4k
Suzy Elhlou	Finance Manager	no data	geen gegevens	geen gegevens
Mathew Watkins	Company Secretary	less than a year	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van AT1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Kelly	Founder	14.6yrs	AU$476.48k	1.15% A$ 147.4k
Deborah Neff	Independent Non-Executive Director	3.2yrs	AU$90.00k	geen gegevens
Cheri Walker	Independent Non-Executive Director	2yrs	AU$50.00k	geen gegevens
Paul Kasian	Independent Non-Executive Director	4.8yrs	AU$70.00k	0.016% A$ 2.0k
John Keith	Independent Non-Executive Chairman	12.9yrs	AU$130.00k	0.51% A$ 65.2k
Ian Boulton	Member of Advisory Board	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van AT1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Atomo Diagnostics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Atomo Diagnostics Limited, Annual General Meeting, Nov 15, 2024

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

Recent updates

Atomo Diagnostics Limited Receives A $2.44 Million Cooperative Research Centres Projects Grant to Spearhead the Development of A Groundbreaking Rapid Test for Active Syphilis Diagnosis

Atomo Diagnostics Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released: AU$0.011 loss per share (vs AU$0.017 loss in FY 2023)

Atomo Diagnostics Limited to Report Q2, 2025 Results on Jan 31, 2025

New minor risk - Share price stability

Atomo Diagnostics Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Atomo Diagnostics Limited to Report First Half, 2024 Results on Jan 29, 2024

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

New major risk - Market cap size

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.01 loss in FY 2022)

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

New major risk - Share price stability

Atomo Diagnostics Limited to Report Q4, 2023 Results on Jul 31, 2023

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.004 loss in 1H 2022)

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Atomo Diagnostics Limited, Annual General Meeting, Oct 27, 2022

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Forecast breakeven date pushed back to 2024

Atomo Diagnostics Limited Expands Executive Team

No longer forecast to breakeven

First half 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$0.31

Atomo Diagnostics Limited to Report First Half, 2022 Results on Feb 21, 2022

Atomo Diagnostics Limited Receives Approval for its Covid-19 Antigen Test in NZ

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2021 earnings released

Consensus revenue estimates fall to AU$7.20m

Forecast breakeven pushed back to 2023

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to AU$9.60m

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.008 loss in 1H 2020)

Revenue and earnings beat expectations

New 90-day low: AU$0.28

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

New 90-day low: AU$0.29

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

New 90-day low: AU$0.30

Atomo Diagnostics Limited Receives TGA Approval for Atomorapid HIV (1&2) Test

Atomo Diagnostics Limited Receives TGA Approval for Covid19 Antigen Test

New 90-day low: AU$0.33

Atomo Diagnostics Limited Expands Its Existing COVID-19 Rapid Test Partnership with Access Bio LLC

Atomo Diagnostics Limited Enters into an Agreement DIVOC Laboratories to Launch its COVID-19 Antibody Test in the Indian Market

Full year earnings released - AU$0.026 loss per share

Atomo Diagnostics Limited to Report Fiscal Year 2020 Final Results on Nov 02, 2020

New 90-day high - AU$0.45

Atomo Diagnostics Limited to Report Fiscal Year 2020 Results on Aug 31, 2020

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur